Experience with anti-angiogenic therapy of giant cell granuloma of the facial bones.
Interferon alfa-2a inhibits angiogenesis and was discovered through a series of laboratory experiments that began in 1980. It was first used in 1989 in the management of a child with pulmonary haemangiomatosis. Interferon alfa A was then subsequently use to treat life threatening haemangiomas and other vascular tumours in various organs. Kaban reported on anti-angiogenic therapy of a recurrent giant cell tumour of the mandible in a 5 year old girl with interferon alfa-2a reasoning that as it was a rapidly proliferating vascular lesion it could be treated as an haemangioma. This paper reviews the history and role of interferon alfa-2a as an angiogenesis inhibitor in the treatment of complex haemangiomas and presents its use in the successful management of a rapidly growing central giant cell granuloma in a 4 year old boy in Australia.